MED Earnings & Financial Statements
Medifast, Inc.
$11.85
+$0.18(+1.54%)
41
Overall
60
Value
20
Tech
44
Quality
Market Cap
$132.49M
Volume
197.02K
52W Range
$9.22 - $13.60
Target Price
$12.00
MED earnings and financial statements: Medifast, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MED Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $385.79M | $602.46M | $1.07B | $1.60B | $1.53B |
| Cost of revenue | $110.60M | $157.84M | $296.20M | $458.16M | $398.49M |
| Operating income | -$14.21M | $2.88M | $126.40M | $184.81M | $216.24M |
| EBITDA | $3.09M | $11.69M | $139.41M | $195.74M | $223.03M |
| Net income | -$18.67M | $2.09M | $99.42M | $143.57M | $164.03M |
| EPS (diluted) | $-1.70 | $0.19 | $9.10 | $12.73 | $13.89 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $247.97M | $284.21M | $309.91M | $316.21M | $398.33M |
| Total liabilities | $49.05M | $74.10M | $108.43M | $161.17M | $195.85M |
| Shareholders’ equity | $198.92M | $210.11M | $201.48M | $155.04M | $202.47M |
| Cash and equivalents | $89.30M | $90.93M | $94.44M | $87.69M | $104.18M |
| Long-term debt | $6.09M | $9.94M | $16.13M | $20.27M | $26.02M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $6.86M | $24.48M | $147.66M | $194.57M | $94.55M |
| Capital expenditure | -$5.61M | -$7.45M | -$6.48M | -$16.68M | -$34.21M |
| Free cash flow | $1.25M | $17.02M | $141.17M | $177.89M | $60.34M |
| Dividends paid | $195.0K | $715.0K | $73.02M | $71.62M | $63.86M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MED | $11.85 | +1.5% | 197.02K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |